Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cephalochromin is a natural bis-naphthopyrone compound, typically isolated from fungi such as *Cosmospora vilior*. It is being investigated for its potential as an antineoplastic agent, particularly in the treatment of Acute Myeloid Leukemia (AML). The drug's mechanism of action involves inducing extensive mitochondrial damage, reducing mitochondrial mass and membrane potential, and triggering apoptosis and DNA damage. Research indicates that cephalochromin can overcome resistance to the BCL2 inhibitor venetoclax by reducing the expression of resistance-related proteins like MCL1 and inducing autophagy. It has shown synergistic effects when combined with venetoclax in various AML models while sparing healthy peripheral blood mononuclear cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cephalochromin.